Source:http://linkedlifedata.com/resource/pubmed/id/15505610
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2004-10-26
|
pubmed:abstractText |
We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk primary breast cancer patients with > or =10 positive axillary lymph nodes after primary surgery or > or =4 positive axillary lymph nodes after neoadjuvant chemotherapy and surgery. The associations of various potential prognostic factors with the relapse-free survival (RFS) rate and overall survival (OS) rate were determined. Between October 1992 and March 2000, 177 eligible patients (median age, 46 years) were given high-dose CBT followed by AHST. At a median follow-up of 63 months, the acute treatment-related mortality was 4.5%. Estimated 5-year RFS and OS rates were 62% and 68%, respectively, for all patients. For patients with > or =10 positive axillary lymph nodes after primary surgery, the 5-year RFS and OS rates were 71% and 70%, respectively, and for patients with > or =4 positive axillary lymph nodes after neoadjuvant chemotherapy, the 5-year RFS and OS rates were 53% and 66%, respectively. In 2-sided log-rank tests, earlier disease stage, a lower lymph node ratio, and a lower tumor score were associated with a prolonged RFS and OS. In a multivariate proportional hazards model, disease stage and lymph node ratio remained significant. We concluded that high-dose CBT with AHST for high-risk primary breast cancer is feasible, with comparable efficacy to other phase II studies. More than a 50% estimated 5-year survival rate was seen in all high-risk primary breast cancer patients. In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1083-8791
|
pubmed:author |
pubmed-author:ChamplinRichard ERE,
pubmed-author:ChengYee ChungYC,
pubmed-author:DonatoMichele LML,
pubmed-author:GajewskiJames LJL,
pubmed-author:HortobagyiGabriel NGN,
pubmed-author:JonesRoyR,
pubmed-author:RondónGabrielaG,
pubmed-author:ShpallElizabeth JEJ,
pubmed-author:SmithTerry LTL,
pubmed-author:UenoNaoto TNT,
pubmed-author:YangYingY
|
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
794-804
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:15505610-Adult,
pubmed-meshheading:15505610-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15505610-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15505610-Breast Neoplasms,
pubmed-meshheading:15505610-Carmustine,
pubmed-meshheading:15505610-Chemotherapy, Adjuvant,
pubmed-meshheading:15505610-Cyclophosphamide,
pubmed-meshheading:15505610-Disease-Free Survival,
pubmed-meshheading:15505610-Female,
pubmed-meshheading:15505610-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15505610-Humans,
pubmed-meshheading:15505610-Middle Aged,
pubmed-meshheading:15505610-Thiotepa,
pubmed-meshheading:15505610-Transplantation, Homologous
|
pubmed:year |
2004
|
pubmed:articleTitle |
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
|
pubmed:affiliation |
Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase II
|